Amneal Completes Acquisition Of Kashiv

Amneal Pharmaceuticals has finalized its acquisition of Kashiv BioSciences for up to $1.1 billion, creating what the company describes as a fully integrated global biosimilars platform. The deal positions Amneal to launch multiple biosimilar products annually and capitalize on an unprecedented wave of biologic patent expirations in the coming years.